uu.seUppsala University Publications
Change search
Link to record
Permanent link

Direct link
BETA
Nilsson, G
Alternative names
Publications (10 of 12) Show all publications
Nilsson, G. & Dahlin, J. S. (2019). New insights into the origin of mast cells [Letter to the editor]. Allergy. European Journal of Allergy and Clinical Immunology, 74(4), 844-845
Open this publication in new window or tab >>New insights into the origin of mast cells
2019 (English)In: Allergy. European Journal of Allergy and Clinical Immunology, ISSN 0105-4538, E-ISSN 1398-9995, Vol. 74, no 4, p. 844-845Article in journal, Letter (Refereed) Published
Place, publisher, year, edition, pages
WILEY, 2019
National Category
Respiratory Medicine and Allergy
Identifiers
urn:nbn:se:uu:diva-382019 (URN)10.1111/all.13668 (DOI)000462915600026 ()30427067 (PubMedID)
Available from: 2019-04-18 Created: 2019-04-18 Last updated: 2019-04-18Bibliographically approved
Ravindran, A., Rönnberg, E., Dahlin, J. S., Mazzurana, L., Säfholm, J., Orre, A.-C., . . . Nilsson, G. (2018). An Optimized Protocol for the Isolation and Functional Analysis of Human Lung Mast Cells. Frontiers in Immunology, 9, Article ID 2193.
Open this publication in new window or tab >>An Optimized Protocol for the Isolation and Functional Analysis of Human Lung Mast Cells
Show others...
2018 (English)In: Frontiers in Immunology, ISSN 1664-3224, E-ISSN 1664-3224, Vol. 9, article id 2193Article in journal (Refereed) Published
Abstract [en]

Background: Mast cells are tissue-resident inflammatory cells defined by their high granularity and surface expression of the high-affinity IgE receptor, Fc + RI, and CD117/KIT, the receptor for stem cell factor (SCF). There is a considerable heterogeneity among mast cells, both phenotypically and functionally. Human mast cells are generally divided into two main subtypes based on their protease content; the mucosa-associated MCT (tryptase positive and chymase negative mast cell) and the connective tissue associated-residing MCTC (tryptase and chymase positive mast cell). Human lung mast cells exhibit heterogeneity in terms of cellular size, expression of cell surface receptors, and secreted mediators. However, knowledge about human lung mast cell heterogeneity is restricted to studies using immunohistochemistry or purified mast cells. Whereas the former is limited by the number of cellular markers that can be analyzed simultaneously, the latter suffers from issues related to cell yield.

Aim: To develop a protocol that enables isolation of human lung mast cells at high yields for analysis of functional properties and detailed analysis using single-cell based analyses of protein (flow cytometry) or RNA (RNA-sequencing) expression.

Methods: Mast cells were isolated from human lung tissue by a sequential combination of washing, enzymatic digestion, mechanical disruption, and density centrifugation using Percoll (WEMP). As a comparison, we also isolated mast cells using a conventional enzyme-based protocol. The isolated cells were analyzed by flow cytometry.

Results: We observed a significant increase in the yield of total human lung CD45(+) immune cells and an even more pronounced increase in the yield of CD117(+) mast cells with the WEMP protocol in comparison to the conventional protocols. In contrast, the frequency of the rare lymphocyte subset innate lymphoid cells group 2 (ILC2) did not differ between the two methods.

Conclusion: The described WEMP protocol results in a significant increase in the yield of human lung mast cells compared to a conventional protocol. Additionally, the WEMP protocol enables simultaneous isolation of different immune cell populations such as lymphocytes, monocytes, and granulocytes while retaining their surface marker expression that can be used for advanced single-cell analyses including multi-color flow cytometry and RNA-sequencing.

Place, publisher, year, edition, pages
FRONTIERS MEDIA SA, 2018
Keywords
mast cells, lung, enzymatic digestion protocols, human mast cells, mast cell isolation
National Category
Immunology
Identifiers
urn:nbn:se:uu:diva-367035 (URN)10.3389/fimmu.2018.02193 (DOI)000446444600001 ()30344519 (PubMedID)
Funder
Swedish Research CouncilSwedish Foundation for Strategic Research Swedish Heart Lung FoundationAstraZenecaScience for Life Laboratory - a national resource center for high-throughput molecular bioscienceThe Karolinska Institutet's Research Foundation
Available from: 2018-11-29 Created: 2018-11-29 Last updated: 2018-11-29Bibliographically approved
Halova, I., Rönnberg, E., Draberova, L., Vliagoftis, H., Nilsson, G. P. & Draber, P. (2018). Changing the threshold-Signals and mechanisms of mast cell priming. Immunological Reviews, 282(1), 73-86
Open this publication in new window or tab >>Changing the threshold-Signals and mechanisms of mast cell priming
Show others...
2018 (English)In: Immunological Reviews, ISSN 0105-2896, E-ISSN 1600-065X, Vol. 282, no 1, p. 73-86Article in journal (Refereed) Published
Abstract [en]

Mast cells play a key role in allergy and other inflammatory diseases involving engagement of multivalent antigen with IgE bound to high-affinity IgE receptors (FcεRIs). Aggregation of FcεRIs on mast cells initiates a cascade of signaling events that eventually lead to degranulation, secretion of leukotrienes and prostaglandins, and cytokine and chemokine production contributing to the inflammatory response. Exposure to pro-inflammatory cytokines, chemokines, bacterial and viral products, as well as some other biological products and drugs, induces mast cell transition from the basal state into a primed one, which leads to enhanced response to IgE-antigen complexes. Mast cell priming changes the threshold for antigen-mediated activation by various mechanisms, depending on the priming agent used, which alone usually do not induce mast cell degranulation. In this review, we describe the priming processes induced in mast cells by various cytokines (stem cell factor, interleukins-4, -6 and -33), chemokines, other agents acting through G protein-coupled receptors (adenosine, prostaglandin E2, sphingosine-1-phosphate, and β-2-adrenergic receptor agonists), toll-like receptors, and various drugs affecting the cytoskeleton. We will review the current knowledge about the molecular mechanisms behind priming of mast cells leading to degranulation and cytokine production and discuss the biological effects of mast cell priming induced by several cytokines.

Place, publisher, year, edition, pages
John Wiley & Sons, 2018
Keywords
cell priming, chemokines, cytokine receptors, cytokines, high-affinity IgE receptor, mast cell
National Category
Immunology in the medical area
Identifiers
urn:nbn:se:uu:diva-343008 (URN)10.1111/imr.12625 (DOI)000424876400006 ()29431203 (PubMedID)
Funder
Swedish Research Council, K2012-57X-13029-14-6
Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2018-05-15Bibliographically approved
Grootens, J., Ungerstedt, J. S., Nilsson, G. & Dahlin, J. S. (2018). Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells. BLOOD ADVANCES, 2(17), 2273-2281
Open this publication in new window or tab >>Deciphering the differentiation trajectory from hematopoietic stem cells to mast cells
2018 (English)In: BLOOD ADVANCES, ISSN 2473-9529, Vol. 2, no 17, p. 2273-2281Article, review/survey (Refereed) Published
Abstract [en]

Hematopoietic stem cells differentiate into all types of blood cells, including peripheral tissue-resident mast cells. The early mast cell differentiation takes place in the bone marrow, after which the progenitor cells enter the circulation and mature once reaching their target organ. Early results from single-cell culture experiments and colony-forming assays have produced the classic hierarchical tree model of hematopoiesis. The introduction of high-throughput, single-cell RNA sequencing is now revolutionizing our understanding of the differentiation process, questioning the classic tree-based models. By integrating the results from early cell culture experiments with single-cell transcriptomics, we present a differentiation landscape model of hematopoiesis and discuss it with focus on mast cells. The review also describes how the hematologic neoplasm systemic mastocytosis can be used to model human hematopoiesis using naturally occurring cell barcoding by means of the common KIT D816V mutation.

Place, publisher, year, edition, pages
AMER SOC HEMATOLOGY, 2018
National Category
Hematology
Identifiers
urn:nbn:se:uu:diva-367138 (URN)10.1182/bloodadvances.2018019539 (DOI)000444247300012 ()30206100 (PubMedID)
Funder
Swedish Research CouncilSwedish Cancer SocietyTore Nilsons Stiftelse för medicinsk forskningMagnus Bergvall Foundation
Available from: 2018-11-29 Created: 2018-11-29 Last updated: 2018-11-29Bibliographically approved
Zoltowska Nilsson, A. M., Lei, Y., Adner, M. & Nilsson, G. P. (2018). Mast cell dependent IL-33/ST2 signaling is protective against the development of airway hyperresponsiveness in a house dust mite mouse model of asthma. American Journal of Physiology - Lung cellular and Molecular Physiology, 314(3), L484-L492
Open this publication in new window or tab >>Mast cell dependent IL-33/ST2 signaling is protective against the development of airway hyperresponsiveness in a house dust mite mouse model of asthma
2018 (English)In: American Journal of Physiology - Lung cellular and Molecular Physiology, ISSN 1040-0605, E-ISSN 1522-1504, Vol. 314, no 3, p. L484-L492Article in journal (Refereed) Published
Abstract [en]

Interleukin-33 (IL-33) and its receptor ST2 have been influentially associated to the pathophysiology of asthma. Due to the divergent roles of IL-33 in regulating mast cell functions, there is a need to further characterize IL-33/ST2-dependent mast cell responses and their significance in the context of asthma. This study aimed to investigate how IL-33/ST2-dependent mast cell responses contribute to the development of airway hyperresponsiveness (AHR) and airway inflammation in a mouse model of house dust mite (HDM) induced asthma. Mast cell deficient C57BL/6-KitW-sh (Wsh) mice engrafted with either wild-type (Wsh+MC-WT) or ST2 deficient bone marrow derived mast cells (Wsh+MC-ST2KO) were exposed to HDM delivered intranasally. An exacerbated development of AHR in response to HDM was seen in Wsh+MC-ST2KO compared to Wsh+MC-WT mice. The contribution of this IL-33/ST2-dependent mast cell response to AHR seems to reside within the smaller airways in the peripheral parts of the lung, as suggested by the isolated yet marked effect on tissue resistance. Considering the absence of a parallel increase in cellular inflammation in BALF and lung, the aggravated AHR in Wsh+MC-ST2KO mice, seems to be independent of cellular inflammation. We observed an association between the elevated AHR and reduced PGE2 levels in bronchoalveolar lavage fluid. Due to the protective properties of PGE2 in airway responses, it is conceivable that IL-33/ST2-dependent mast cell induction of PGE2 could be responsible for the dampening effect on AHR. In conclusion, we reveal that IL-33/ST2-dependent mast cell responses can have a protective, rather than causative role in the development of AHR.

Keywords
HDM mouse model, IL-33, ST2, airway hyperresponsiveness (AHR), mast cells
National Category
Respiratory Medicine and Allergy
Identifiers
urn:nbn:se:uu:diva-343006 (URN)10.1152/ajplung.00270.2017 (DOI)000428403800014 ()29146574 (PubMedID)
Funder
Swedish Research CouncilSwedish Heart Lung FoundationThe Karolinska Institutet's Research Foundation
Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2018-07-19Bibliographically approved
Wennstig, A. K., Garmo, H., Isacsson, U., Gagliardi, G., Rintela, N., Lagerqvist, B., . . . Nilsson, G. (2018). The relationship between radiation doses to coronary arteries and later intervention requiring coronary stenosis in breast cancer. Paper presented at 11th European Breast Cancer Conference (EBCC), MAR 21-23, 2018, Barcelona, SPAIN. European Journal of Cancer, 92, S61-S62
Open this publication in new window or tab >>The relationship between radiation doses to coronary arteries and later intervention requiring coronary stenosis in breast cancer
Show others...
2018 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 92, p. S61-S62Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
ELSEVIER SCI LTD, 2018
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-357181 (URN)000429103100150 ()
Conference
11th European Breast Cancer Conference (EBCC), MAR 21-23, 2018, Barcelona, SPAIN
Available from: 2018-08-14 Created: 2018-08-14 Last updated: 2018-08-14Bibliographically approved
Gülen, T., Möller Westerberg, C., Lyberg, K., Ekoff, M., Kolmert, J., Bood, J., . . . Dahlén, B. (2017). Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.. Clinical and Experimental Allergy, 47(7), 909-917
Open this publication in new window or tab >>Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis.
Show others...
2017 (English)In: Clinical and Experimental Allergy, ISSN 0954-7894, E-ISSN 1365-2222, Vol. 47, no 7, p. 909-917Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Patients with systemic mastocytosis (SM) have clinical signs of mast cell (MC) activation and increased levels of MC mediators. It is unclear whether the increased mediator levels are caused by increased numbers of tissue MCs, or whether these cells in affected individuals have a hyperactive phenotype.

OBJECTIVE: To determine reactivity of the skin and the airways to directly acting mediators and indirectly acting mast cell secretagogues in subjects with SM.

METHODS: were measured, as well as ex vivo basophil histamine release.

RESULTS: Mast cell mediators in the blood and urine were significantly higher in patients with SM than in HC and A controls. Responsiveness to local activation of skin MCs (by morphine) and airway MCs (by mannitol) was similar in SM and HC groups. Likewise, end-organ responsiveness in the skin to histamine, and in the airways to methacholine, was similar in all three subject groups. There was no evidence of increased basophil reactivity in SM patients.

CONCLUSIONS AND CLINICAL RELEVANCE: Mast cells in the skin and airways of subjects with SM do not exhibit hyper-reactivity towards the MC-activating stimuli morphine and mannitol, respectively. Therefore, the highly elevated baseline levels of MC mediators in SM are most likely due to increased MC numbers, rather than altered MC responsiveness. The underlying mechanisms could involve leakage of MC mediators, or dysfunctions in mediator synthesis, storage and release. One clinical implication of our study is that there is no contraindication to perform skin tests using morphine in subjects with mastocytosis.

Keywords
histamine, mannitol, mast cell reactivity, mastocytosis, prostaglandin D2, tryptase
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:uu:diva-343002 (URN)10.1111/cea.12914 (DOI)28258965 (PubMedID)
Funder
Swedish Research CouncilSwedish Cancer SocietyStockholm County CouncilSwedish Heart Lung Foundation
Note

De två sista författarna delar sistaförfattarskapet.

Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2018-03-16Bibliographically approved
Lyberg, K., Ali, H. A., Grootens, J., Kjellander, M., Tirfing, M., Arock, M., . . . Ungerstedt, J. (2017). Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.. OncoTarget, 8(6), 9647-9659
Open this publication in new window or tab >>Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Show others...
2017 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 8, no 6, p. 9647-9659Article in journal (Refereed) Published
Abstract [en]

Systemic mastocytosis (SM) is a clonal bone marrow disorder, where therapeutical options are limited. Over 90% of the patients carry the D816V point mutation in the KIT receptor that renders this receptor constitutively active. We assessed the sensitivity of primary mast cells (MC) and mast cell lines HMC1.2 (D816V mutated), ROSA (KIT WT) and ROSA (KIT D816V) cells to histone deacetylase inhibitor (HDACi) treatment. We found that of four HDACi, suberoyl anilide hydroxamic acid (SAHA) was the most effective in killing mutated MC. SAHA downregulated KIT, followed by major MC apoptosis. Primary SM patient MC cultured ex vivo were even more sensitive to SAHA than HMC1.2 cells, whereas primary MC from healthy subjects were less affected. There was a correlation between cell death and SM disease severity, where cell death was more pronounced in the case of aggressive SM, with almost 100% cell death among MC from the mast cell leukemia patient. Additionally, ROSA (KIT D816V) was more affected by HDACi than ROSA (KIT WT) cells. Using ChIP qPCR, we found that the level of active chromatin mark H3K18ac/H3 decreased significantly in the KIT region. This epigenetic silencing was seen only in the KIT region and not in control genes upstream and downstream of KIT, indicating that the downregulation of KIT is exerted by specific epigenetic silencing. In conclusion, KIT D816V mutation sensitized MC to HDACi mediated killing, and SAHA may be of value as specific treatment for SM, although the specific mechanism of action requires further investigation.

National Category
Cancer and Oncology Cell Biology
Identifiers
urn:nbn:se:uu:diva-311794 (URN)10.18632/oncotarget.14181 (DOI)000394181800062 ()28038453 (PubMedID)
Available from: 2017-01-02 Created: 2017-01-02 Last updated: 2017-11-29Bibliographically approved
Sjöberg, L. C., Nilsson, A. Z., Lei, Y., Gregory, J. A., Adner, M. & Nilsson, G. P. (2017). Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, inflammation and remodeling in a mouse model of asthma. Scientific Reports, 7(1), Article ID 4219.
Open this publication in new window or tab >>Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, inflammation and remodeling in a mouse model of asthma
Show others...
2017 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 7, no 1, article id 4219Article in journal (Refereed) Published
Abstract [en]

Interleukin 33 (IL-33) represents a potential link between the airway epithelium and induction of Th2-type inflammatory responses associated with the development of asthma. This study investigated the potential of IL-33 to exacerbate antigen driven asthma responses. An ovalbumin (OVA) asthma model was used in which sensitized C57BL/6 mice were exposed to IL-33 before each OVA challenge. IL-33 given to sensitized mice acted synergistically with antigen and aggravated airway inflammation, hyperresponsiveness and remodeling compared with mice that were only OVA sensitized and challenged and mice that were only exposed to IL-33. Elevated levels of local and systemic mast cell protease mMCP-1, as well as antigen-specific IgE production, were observed following IL-33 administration to sensitized mice. Similarly, exposing OVA-sensitized mice to IL-33 increased the Th2 cytokine levels, including IL-4, IL-5 and IL-13. Furthermore, IL-33 and OVA administration to OVA-sensitized mice increased ILC2s in the lung, suggesting a role for ILC2s in IL-33-mediated exacerbation of OVA-induced airway responses. Collectively, these findings show that IL-33 aggravates important features of antigen-driven asthma, which may have implications for asthma exacerbations.

National Category
Respiratory Medicine and Allergy
Identifiers
urn:nbn:se:uu:diva-343005 (URN)10.1038/s41598-017-03674-0 (DOI)000404037000005 ()28652606 (PubMedID)
Funder
Swedish Research CouncilSwedish Heart Lung Foundation
Available from: 2018-02-24 Created: 2018-02-24 Last updated: 2018-03-22Bibliographically approved
Dahlin, J. S., Ekoff, M., Grootens, J., Löf, L., Amini, R.-M., Hagberg, H., . . . Nilsson, G. (2017). KIT signaling is dispensable for human mast cell progenitor development. Blood, 130(16), 1785-1794
Open this publication in new window or tab >>KIT signaling is dispensable for human mast cell progenitor development
Show others...
2017 (English)In: Blood, ISSN 0006-4971, E-ISSN 1528-0020, Vol. 130, no 16, p. 1785-1794Article in journal (Refereed) Published
Abstract [en]

Human hematopoietic progenitors are generally assumed to require stem cell factor (SCF) and KIT signaling during differentiation for the formation of mast cells. Imatinib treatment, which inhibits KIT signaling, depletes mast cells in vivo. Furthermore, the absence of SCF or imatinib treatment prevents progenitors from developing into mast cells in vitro. However, these observations do not mean that mast cell progenitors require SCF and KIT signaling throughout differentiation. Here, we demonstrate that circulating mast cell progenitors are present in patients undergoing imatinib treatment. In addition, we show that mast cell progenitors from peripheral blood survive, mature, and proliferate without SCF and KIT signaling in vitro. Contrary to the prevailing consensus, our results show that SCF and KIT signaling are dispensable for early mast cell development.

National Category
Hematology Clinical Laboratory Medicine
Research subject
Pathology
Identifiers
urn:nbn:se:uu:diva-339750 (URN)10.1182/blood-2017-03-773374 (DOI)000413246200005 ()28790106 (PubMedID)
Funder
Swedish Research CouncilSwedish Cancer SocietyCancer and Allergy FoundationThe Cancer Society in StockholmThe Cancer Research Funds of RadiumhemmetThe Karolinska Institutet's Research Foundation
Available from: 2018-01-25 Created: 2018-01-25 Last updated: 2019-03-29Bibliographically approved
Organisations

Search in DiVA

Show all publications